On November 9, 2021 Nektar Therapeutics (NASDAQ:NKTR) reported that it will host a webcast analyst and investor conference call with a cancer specialist and Nektar management on Friday, November 12, 2021, at 12:00 p.m. EST during the 2021 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting (Press release, Nektar Therapeutics, NOV 9, 2021, https://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-webcast-conference-call-for-analysts–investors-with-cancer-specialist-during-2021-society-for-immunotherapy-of-cancer-sitc-36th-annual-meeting-301419303.html [SID1234594922]). The call will be hosted by Nektar management and will include, SITC (Free SITC Whitepaper) author and presenter, Dr. Mehmet Altan, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas Anderson Cancer Center and Dr. Alan Tan, Director of GU Medical Oncology and Assistant Professor in the Division of Hematology, Oncology and Cell Therapy at Rush University Medical Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will follow the publication of the NKTR-255 poster (Abstract #957) on Friday morning. SITC (Free SITC Whitepaper) is being held in Washington, D.C. and virtually from November 10 to November 14, 2021.

Analyst Call:

Date and Time: Friday, November 12, 2021, at 12:00 p.m. EST

Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (enter access code 1769208)

Investors and analysts can also view slides and listen to the live audio webcast of the presentation at View Source The event will also be available for replay for two weeks on Nektar’s website: www.nektar.com.

Details of the presentations at SITC (Free SITC Whitepaper) are as follows:

Nektar Poster Presentations at SITC (Free SITC Whitepaper)

Abstract 957: "NKTR-255 Plus Cetuximab in Patients with Solid Tumors: Interim Safety and Efficacy Results from the Phase 1b Dose Escalation Study," Altan, M., et al.

Presenter: Dr. Mehmet Altan, MD Anderson Cancer Center
ePoster and live poster will be available on Friday, November 12th, 2021, at 7:00 a.m. EST
Poster reception: Friday, November 12, 2021, from 7:00 p.m. – 8:30 p.m. EST
Additional Collaborator Presentations at SITC (Free SITC Whitepaper)

Abstract 59: "Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial," Feils, AS., et al.

ePoster will be on display on the SITC (Free SITC Whitepaper) 2021 virtual meeting platform on Friday, November 12, 2021, at 7:00 a.m. EST
Abstract 596: "Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity," Rolig, A., et al.

ePoster will be on display on the SITC (Free SITC Whitepaper) 2021 virtual meeting platform on Friday, November 12, 2021, at 7:00 a.m. EST
Dr. Mehmet Altan

Mehmet Altan, MD, is an Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas Anderson Cancer Center. Dr. Altan is one of the lead investigators in the phase 1/2, dose-escalation and dose-expansion study of NKTR-255 in combination with cetuximab in patients with refractory 2nd and 3rd line metastatic colorectal cancer or metastatic head and neck cancer. His current research areas include identification of mechanisms for primary and secondary resistance to immunotherapies and predictive markers for immunotherapy toxicities. He also works on translational research projects for identification of spatiotemporal dynamics of the tumor microenvironment in response to immunotherapy to define potential therapeutic targets.

Dr. Alan Tan

Alan Tan, MD, is a Director of GU Medical Oncology and an Assistant Professor in the Division of Hematology, Oncology and Cell Therapy at Rush University Medical Center. He specializes in kidney cancer, urothelial/bladder cancer, prostate cancer and melanoma. Dr. Tan has clinical research interest in designing and implementing clinical trials to test novel immunotherapies and targeted therapies in these cancers. He also leads the Rush University Precision Oncology and Genomics program. He is co-chair for the Hoosier Cancer Research Network (HCRN) Melanoma Working Group.